1. New Brazilian variant P1 SARS-CoV-2
Threats and Challenges
Alexandre Naime Barbosa MD, PhD
Infectious Diseases Professor
Pre-ECCMID Day on COVID-19
Worshop South America – API/SBI
May/2021 - On-Line - ECCMID

2. Disclosures
Works as:
- Professor and Head of the Infectious Diseases Department at Sao Paulo State University
(UNESP)
- Scientific Medical Coordinator for COVID-19 - UNESP General Hospital (HC UNESP)
- Medical Consultant for COVID-19 - Brazilian Society of Infectious Diseases (SBI)
- Member of the Covid-19 Extraordinary Monitoring Committee of the Brazilian Medical
Association (AMB)
- Link for Scientifics CVs and Media Contributions: https://linktr.ee/dralexandrebarbosa
No Potential Conflicts of Interest for this Presentation

3. SARS-COV-2: Emergence of New Variants
https://www.who.int/news-room/events/detail/2021/02/03/default-calendar/sars-cov-2-virus-mutations-and-variants

4. SARS-COV-2: Genomic Epidemiology (Geography)

5. SARS-COV-2: Genomic Epidemiology (Phylogeny)

6. SARS-COV-2: Genomic Epidemiology (Mutation Rate)

7. SARS-COV-2: In Vitro Responses

8. SARS-COV-2: Classification for Variants
https://www.medscape.com/viewarticle/947650
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html

9. SARS-COV-2: Global Distribution of VOCs
https://www.who.int/news-room/events/detail/2021/02/03/default-calendar/sars-cov-2-virus-mutations-and-variants

10. SARS-COV-2: Main VOCs Reported
U.K. - B.1.1.7
South Africa- B.1.351
Brazil - P1
California 1/2 - B.1.427/9
India - B.1617
?
Personal Sllide
Global Dissemination

11. SARS-COV-2: VOCs Genetic Comparison
https://www.niid.go.jp/niid/en/2019-ncov-e/10108-covid19-33-en.html

12. Secretaria de Vigilância em Saúde – Ministério da Saúde – 2021
SARS-COV-2: P1 VOC First Detection
https://www.niid.go.jp/niid/en/2019-ncov-e/10108-covid19-33-en.html

13. SARS-COV-2: P1 First Evidence of ↑ Transmission

14. SARS-COV-2: Higher P1 VL (10x) than non P1

15. SARS-COV-2: P1 ↑ Transmissibility and Reinfection

16. SARS-COV-2: P1 ↑ Transmissibility

17. SARS-COV-2: Prevalence in SP State Nowadays
https://www.saopaulo.sp.gov.br/noticias-coronavirus/governo-de-sp-conclui-estudo-sobre-variantes-do-novo-coronavirus-no-estado/

18. https://portal.fiocruz.br/sites/portal.fiocruz.br/files/documentos/comunicado_variantes_de_preocupacao_fiocruz_2_2021-03-04.pdf
SARS-COV-2: Prevalence in Brazil Nowadays

19. SARS-COV-2: Daily Deaths in Brazil
05/05/2021
https://covid19.healthdata.org/
05/05/2021
15.000.000 410.000

20. SARS-COV-2: P1 Potential Impact on Vaccine Efficacy
https://www.medscape.com/viewarticle/948335

21. SARS-COV-2: P1 Impact on Coronavac Efficacy (?)

22. SARS-COV-2: Coronavac Effectiveness against P1

23. SARS-COV-2: P1 Impact on ChAdOx1/RNA Vaccines (?)
https://reference.medscape.com/viewarticle/949943

24. SARS-COV-2: ChAdOx1 Effectiveness against P1

25. SARS-COV-2: P1 Impacts on Monoclonal Ab Therapy
https://reference.medscape.com/viewarticle/949943

26. P1 SARS-COV-2 Variant: Conclusion
 SARS-COV-2: Emergence of new variants is to be expected
 P1 VOC: Higher SARS-COV-2 Viral Load (10x)
 P1 VOC: Higher Rate of Transmissibility (2,5x)
 P1 VOC: More chance of Reinfection (6,4%)
 P1 VOC: Impact on Vaccine and Ab Therapy Efficacy (in vitro)
 P1 VOC: Effectiveness of Coronavac apparently not affected

27. Thanks!
SAE de Infectologia UNESP HC UNESP Botucatu Faculdade de Medicina UNESP
@dr.alexandre.naime.barbosa @drbarbosa
Alexandre Naime Barbosa
Dr. Alexandre Naime Barbosa